Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Protein Effect||no effect|
|Gene Variant Descriptions||NRAS amplification indicates an increased number of copies of the NRAS gene. However, the mechanism causing the increase is unspecified.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NRAS amp||melanoma||predicted - sensitive||Binimetinib||Preclinical - Pdx||Actionable||In a preclinical study, Mektovi (binimetinib) treatment resulted in reduced tumor growth and proliferation in two patient-derived xenograft (PDX) melanoma models with NRAS copy number gain and without BRAF or NRAS mutations (PMID: 29245078).||29245078|
|FGFR1 amp NRAS amp||lung non-small cell carcinoma||sensitive||Infigratinib + Trametinib||Preclinical - Cell culture||Actionable||In a preclinical study, Truseltiq (infigratinib) and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification in culture (PMID: 28630215).||28630215|
|FGFR1 amp NRAS amp||lung non-small cell carcinoma||resistant||Infigratinib||Preclinical - Cell culture||Actionable||In a preclinical study, amplification of NRAS was identified in a non-small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to Truseltiq (infigratinib) in culture (PMID: 28630215).||28630215|
|FGFR1 amp NRAS amp||lung non-small cell carcinoma||resistant||Trametinib||Preclinical - Cell culture||Actionable||In a preclinical study, non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification were resistant to Mekinist (trametinib) in culture (PMID: 28630215).||28630215|
|BRAF V600E NRAS amp||colorectal cancer||predicted - resistant||Panitumumab + Vemurafenib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 16 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).||28951457|